Ontario-based blood testing upstart Vital Biosciences revealed it has $48 million in funding, including a fresh $18.56 million Series A round led by Lachy Groom and Northpond Ventures. Lest readers forget the initial premise of Theranos, the company's initial goal was laudable: Disrupt the $74 billion lab testing industry controlled by behemoths Quest and LabCorp, and put preventive care in patients' hands.
Blood testing startup Vital Biosciences collects $48M